{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:38:50Z","timestamp":1791826730183,"version":"4.3.4"},"reference-count":68,"publisher":"Portland Press Ltd.","issue":"20","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna Therapeutics","doi-asserted-by":"crossref","award":["XXX"],"award-info":[{"award-number":["XXX"]}],"id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ramon y Cajal Program","award":["RYC2018-024475-I"],"award-info":[{"award-number":["RYC2018-024475-I"]}]},{"name":"Sara Borrell Contract","award":["CD22\/00109"],"award-info":[{"award-number":["CD22\/00109"]}]},{"name":"Fundacion Cient\u00edfica AECC","award":["POSTD18014AREC"],"award-info":[{"award-number":["POSTD18014AREC"]}]},{"DOI":"10.13039\/501100017266","name":"Gobierno de Navarra","doi-asserted-by":"crossref","award":["ARNMUNE Ref.: 0011-1411-2023-000032"],"award-info":[{"award-number":["ARNMUNE Ref.: 0011-1411-2023-000032"]}],"id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI22\/00147"],"award-info":[{"award-number":["PI22\/00147"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Metabolic dysfunction-associated steatohepatitis (MASH) represents a global health threat. MASH pathophysiology involves hepatic lipid accumulation and progression to severe conditions like cirrhosis and, eventually, hepatocellular carcinoma. Fibroblast growth factor (FGF)-19 has emerged as a key regulator of metabolism, offering potential therapeutic avenues for MASH and associated disorders. We evaluated the therapeutic potential of non-mitogenic (NM)-FGF19 mRNA formulated in liver-targeted lipid nanoparticles (NM-FGF19-mRNAs-LNPs) in C57BL\/6NTac male mice with diet-induced obesity and MASH (DIO-MASH: 40% kcal fat, 20% kcal fructose, 2% cholesterol). After feeding this diet for 21 weeks, NM-FGF19-mRNAs-LNPs or control (C-mRNA-LNPs) were administered (0.5 mg\/kg, i.v.) weekly for another six weeks, in which diet feeding continued. NM-FGF19-mRNAs-LNPs treatment in DIO-MASH mice resulted in reduced body weight, adipose tissue depots, and serum transaminases, along with improved insulin sensitivity. Histological analyses confirmed the reversal of MASH features, including steatosis reduction without worsening fibrosis. NM-FGF19-mRNAs-LNPs reduced total hepatic bile acids (BAs) and changed liver BA composition, markedly influencing cholesterol homeostasis and metabolic pathways as observed in transcriptomic analyses. Extrahepatic effects included the down-regulation of metabolic dysfunction-associated genes in adipose tissue. This study highlights the potential of NM-FGF19-mRNA-LNPs therapy for MASH, addressing both hepatic and systemic metabolic dysregulation. NM-FGF19-mRNA demonstrates efficacy in reducing liver steatosis, improving metabolic parameters, and modulating BA levels and composition. Given the central role played by BA in dietary fat absorption, this effect of NM-FGF19-mRNA may be mechanistically relevant. Our study underscores the high translational potential of mRNA-based therapies in addressing the multifaceted landscape of MASH and associated metabolic perturbations.<\/jats:p>","DOI":"10.1042\/cs20241137","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T08:36:52Z","timestamp":1726821412000},"page":"1265-1284","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)"],"prefix":"10.1042","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6091-8225","authenticated-orcid":false,"given":"Amaya","family":"Lopez-Pascual","sequence":"first","affiliation":[{"name":"1Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain"},{"name":"2Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan\u00a0S.","family":"Russo-Cabrera","sequence":"additional","affiliation":[{"name":"3Immunology and Immunotherapy Program, CIMA, CCUN, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Ardaiz","sequence":"additional","affiliation":[{"name":"3Immunology and Immunotherapy Program, CIMA, CCUN, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Palmer","sequence":"additional","affiliation":[{"name":"4Moderna Inc, Cambridge, Massachusetts, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Renee","family":"Graham","sequence":"additional","affiliation":[{"name":"4Moderna Inc, Cambridge, Massachusetts, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iker","family":"Uriarte","sequence":"additional","affiliation":[{"name":"1Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain"},{"name":"5CIBERehd, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Gomar","sequence":"additional","affiliation":[{"name":"3Immunology and Immunotherapy Program, CIMA, CCUN, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ruiz-Guillamon","sequence":"additional","affiliation":[{"name":"3Immunology and Immunotherapy Program, CIMA, CCUN, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria\u00a0U.","family":"Latasa","sequence":"additional","affiliation":[{"name":"1Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain"},{"name":"5CIBERehd, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Arechederra","sequence":"additional","affiliation":[{"name":"1Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain"},{"name":"2Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain"},{"name":"5CIBERehd, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Fontanellas","sequence":"additional","affiliation":[{"name":"1Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain"},{"name":"2Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain"},{"name":"5CIBERehd, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria\u00a0J","family":"Monte","sequence":"additional","affiliation":[{"name":"5CIBERehd, Madrid, Spain"},{"name":"6Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, IBSAL, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose\u00a0J.G.","family":"Marin","sequence":"additional","affiliation":[{"name":"5CIBERehd, Madrid, Spain"},{"name":"6Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, IBSAL, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Berasain","sequence":"additional","affiliation":[{"name":"1Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain"},{"name":"5CIBERehd, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos L.","family":"del Rio","sequence":"additional","affiliation":[{"name":"4Moderna Inc, Cambridge, Massachusetts, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite\u00a0G.","family":"Fernandez-Barrena","sequence":"additional","affiliation":[{"name":"1Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain"},{"name":"2Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain"},{"name":"5CIBERehd, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo\u00a0G.V.","family":"Martini","sequence":"additional","affiliation":[{"name":"4Moderna Inc, Cambridge, Massachusetts, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua\u00a0R.","family":"Schultz","sequence":"additional","affiliation":[{"name":"4Moderna Inc, Cambridge, Massachusetts, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Berraondo","sequence":"additional","affiliation":[{"name":"3Immunology and Immunotherapy Program, CIMA, CCUN, University of Navarra, Pamplona, Spain"},{"name":"7CIBERonc, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6570-3557","authenticated-orcid":false,"given":"Matias\u00a0A.","family":"Avila","sequence":"additional","affiliation":[{"name":"1Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain"},{"name":"2Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain"},{"name":"5CIBERehd, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"2024100410253847900_B1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"2024100410253847900_B2","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"Marchesini","year":"2016","journal-title":"J. Hepatol."},{"key":"2024100410253847900_B3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet. Diabetes Endocrinol."},{"key":"2024100410253847900_B4","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/hep.26717","article-title":"Extrahepatic complications of nonalcoholic fatty liver disease","volume":"59","author":"Armstrong","year":"2014","journal-title":"Hepatology"},{"key":"2024100410253847900_B5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2024100410253847900_B6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"2024100410253847900_B7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2024100410253847900_B8","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1089\/ars.2019.7901","article-title":"Oxygen in metabolic dysfunction and its therapeutic relevance","volume":"35","author":"Lopez-Pascual","year":"2021","journal-title":"Antioxid. Redox Signal."},{"key":"2024100410253847900_B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10092418","article-title":"The saga of endocrine fgfs","volume":"10","author":"Phan","year":"2021","journal-title":"Cells"},{"key":"2024100410253847900_B10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"2024100410253847900_B11","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.jhepr.2021.100346","article-title":"New targets for NAFLD","volume":"3","author":"Parlati","year":"2021","journal-title":"JHEP Reports"},{"key":"2024100410253847900_B12","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: current perspectives of resmetirom","author":"Petta","year":"2024","journal-title":"Liver Int."},{"key":"2024100410253847900_B13","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1210\/endo.143.5.8850","article-title":"Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity","volume":"143","author":"Tomlinson","year":"2002","journal-title":"Endocrinology"},{"key":"2024100410253847900_B14","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1210\/en.2003-1671","article-title":"Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes","volume":"145","author":"Fu","year":"2004","journal-title":"Endocrinology"},{"key":"2024100410253847900_B15","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1136\/gutjnl-2016-312975","article-title":"Fibroblast growth factor 15\/19 (FGF15\/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration","volume":"66","author":"Alvarez-Sola","year":"2017","journal-title":"Gut"},{"key":"2024100410253847900_B16","doi-asserted-by":"publisher","first-page":"111617","DOI":"10.1016\/j.mce.2022.111617","article-title":"Fibroblast growth factor 15\/19 expression, regulation, and function: An overview","volume":"548","author":"Guthrie","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"2024100410253847900_B17","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/gutjnl-2012-302945","article-title":"Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice","volume":"62","author":"Uriarte","year":"2013","journal-title":"Gut"},{"key":"2024100410253847900_B18","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1136\/gutjnl-2014-307874","article-title":"Control of hepatocyte proliferation and survival by Fgf receptors is essential for liver regeneration in mice","volume":"64","author":"Padrissa-Alt\u00e9s","year":"2015","journal-title":"Gut"},{"key":"2024100410253847900_B19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000450905","article-title":"Fibroblast growth factor 15\/19 in hepatocarcinogenesis","volume":"35","author":"Alvarez-Sola","year":"2017","journal-title":"Dig. Dis."},{"key":"2024100410253847900_B20","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hep.28257","article-title":"Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice","volume":"63","author":"Zhou","year":"2016","journal-title":"Hepatology"},{"key":"2024100410253847900_B21","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","article-title":"Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19","volume":"74","author":"Zhou","year":"2014","journal-title":"Cancer Res."},{"key":"2024100410253847900_B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms15433","article-title":"Non-cell-autonomous activation of IL-6\/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis","volume":"8","author":"Zhou","year":"2017","journal-title":"Nat. Commun."},{"key":"2024100410253847900_B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.3009098","article-title":"A nontumorigenic variant of FGF19 treats cholestatic liver diseases","volume":"6","author":"Luo","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"2024100410253847900_B24","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/hep4.1108","article-title":"Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice","volume":"1","author":"Zhou","year":"2017","journal-title":"Hepatol. Commun."},{"key":"2024100410253847900_B25","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","article-title":"A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis","volume":"79","author":"Rinella","year":"2024","journal-title":"Hepatology"},{"key":"2024100410253847900_B26","doi-asserted-by":"publisher","first-page":"100255","DOI":"10.1016\/j.jhepr.2021.100255","article-title":"Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases","volume":"3","author":"Sanyal","year":"2021","journal-title":"JHEP Rep."},{"key":"2024100410253847900_B27","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial","author":"Harrison","year":"2022","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"2024100410253847900_B28","doi-asserted-by":"publisher","first-page":"219.e1","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"2024100410253847900_B29","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"2024100410253847900_B30","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jhep.2018.11.032","article-title":"Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis","volume":"70","author":"Rinella","year":"2019","journal-title":"J. Hepatol."},{"key":"2024100410253847900_B31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1194\/jlr.M089961","article-title":"Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis","volume":"60","author":"Zhou","year":"2019","journal-title":"J. Lipid Res."},{"key":"2024100410253847900_B32","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2337\/db18-1305","article-title":"FGF19 analog as a surgical factor mimetic that contributes to metabolic effects beyond glucose homeostasis","volume":"68","author":"DePaoli","year":"2019","journal-title":"Diabetes"},{"key":"2024100410253847900_B33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bbrc.2018.05.121","article-title":"Fibroblast growth factor 19 protects the heart from oxidative stress-induced diabetic cardiomyopathy via activation of AMPK\/Nrf2\/HO-1 pathway","volume":"502","author":"Li","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2024100410253847900_B34","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1136\/gutjnl-2019-318269","article-title":"Messenger RNA therapy for rare genetic metabolic diseases","volume":"68","author":"Berraondo","year":"2019","journal-title":"Gut"},{"key":"2024100410253847900_B35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/bs.ircmb.2022.03.005","article-title":"Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases","volume":"372","author":"C\u00f3rdoba","year":"2022","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"2024100410253847900_B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells11203328","article-title":"mRNA-based approaches to treating liver diseases","volume":"11","author":"Cacicedo","year":"2022","journal-title":"Cells"},{"key":"2024100410253847900_B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-023-00977-5","article-title":"mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications","volume":"30","author":"Wang","year":"2023","journal-title":"J. Biomed. Sci. 2023 301"},{"key":"2024100410253847900_B38","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA Delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"2024100410253847900_B39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/nat.2018.0734","article-title":"MicroRNAs enable mRNA therapeutics to selectively program cancer cells to self-destruct","volume":"28","author":"Jain","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"2024100410253847900_B40","article-title":"Discovery of a novel amino lipid that improves lipid nanoparticle performance through specific interactions with mRNA","volume":"2106727","author":"Cornebise","year":"2021","journal-title":"Adv. Funct. Mater."},{"key":"2024100410253847900_B41","first-page":"388","article-title":"Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: Dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis","volume":"70","author":"Barcena-Varela","year":"2021","journal-title":"Gut"},{"key":"2024100410253847900_B42","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.3390\/cancers12061644","article-title":"Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: a machine-learning approach","volume":"12","author":"Urman","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2024100410253847900_B43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang","year":"2009","journal-title":"Nat. Protoc."},{"key":"2024100410253847900_B44","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jhep.2017.01.027","article-title":"Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19\/FGF15","volume":"66","author":"Zhou","year":"2017","journal-title":"J. Hepatol."},{"key":"2024100410253847900_B45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/apt.15035","article-title":"Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD","volume":"49","author":"Caussy","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2024100410253847900_B46","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.2337\/db13-0639","article-title":"Human insulin resistance is associated with increased plasma levels of 12\u03b1-hydroxylated bile acids","volume":"62","author":"Haeusler","year":"2013","journal-title":"Diabetes"},{"key":"2024100410253847900_B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-43928-7","article-title":"The differential expression of cide family members is associated with nafld progression from steatosis to steatohepatitis","volume":"9","author":"Sans","year":"2019","journal-title":"Sci. Rep."},{"key":"2024100410253847900_B48","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s42255-019-0065-4","article-title":"Gpnmb secreted from liver promotes lipogenesis in white adipose tissue and aggravates obesity and insulin resistance","volume":"1","author":"Gong","year":"2019","journal-title":"Nat. Metab."},{"key":"2024100410253847900_B49","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cphy.c120023","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang","year":"2013","journal-title":"Compr. Physiol."},{"key":"2024100410253847900_B50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1042\/CS20220697","article-title":"Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease","volume":"137","author":"Gillard","year":"2023","journal-title":"Clin. Sci. (Lond.)"},{"key":"2024100410253847900_B51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.molmet.2019.10.009","article-title":"Whole-body and adipose tissue-specific mechanisms underlying the metabolic effects of fibroblast growth factor 21 in the Siberian hamster","volume":"31","author":"Lewis","year":"2020","journal-title":"Mol. Metab."},{"key":"2024100410253847900_B52","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/nm.4363","article-title":"Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice","volume":"23","author":"Benoit","year":"2017","journal-title":"Nat. Med."},{"key":"2024100410253847900_B53","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1111\/jcmm.16448","article-title":"FGF19 protects skeletal muscle against obesity-induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK\/SIRT-1\/PGC-\u03b1 pathway","author":"Guo","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"2024100410253847900_B54","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molmet.2019.09.006","article-title":"The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis","volume":"30","author":"Antonellis","year":"2019","journal-title":"Mol. Metab."},{"key":"2024100410253847900_B55","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S1050-1738(00)00043-8","article-title":"FXR, a bile acid receptor and biological sensor","volume":"10","author":"Tu","year":"2000","journal-title":"Trends Cardiovasc. Med."},{"key":"2024100410253847900_B56","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/cr.2008.289","article-title":"FXR: a metabolic regulator and cell protector","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"key":"2024100410253847900_B57","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.7150\/ijbs.44774","article-title":"Bile acids mediated potential functional interaction between FXR and FATP5 in the regulation of lipid metabolism","volume":"16","author":"Kumari","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"2024100410253847900_B58","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"Jiang","year":"2015","journal-title":"J. Clin. Invest."},{"key":"2024100410253847900_B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0005-2760(87)90002-6","article-title":"beta-Muricholic acid; potentiometric and cholesterol-dissolving properties","volume":"918","author":"Montet","year":"1987","journal-title":"Biochim. Biophys. Acta"},{"key":"2024100410253847900_B60","doi-asserted-by":"publisher","first-page":"1671.e4","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"key":"2024100410253847900_B61","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jcmgh.2021.04.013","article-title":"Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis","volume":"12","author":"Matye","year":"2021","journal-title":"Cmgh"},{"key":"2024100410253847900_B62","doi-asserted-by":"publisher","first-page":"101823","DOI":"10.1016\/j.molmet.2023.101823","article-title":"Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model","volume":"78","author":"Iannone","year":"2023","journal-title":"Mol. Metab."},{"key":"2024100410253847900_B63","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/liv.14802","article-title":"Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease","volume":"41","author":"Sciarrillo","year":"2021","journal-title":"Liver Int."},{"key":"2024100410253847900_B64","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1053\/j.gastro.2007.11.037","article-title":"Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis","volume":"134","author":"Zhou","year":"2008","journal-title":"Gastroenterology"},{"key":"2024100410253847900_B65","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1210\/en.2015-1866","article-title":"Hepatocyte-specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD-fed mice","volume":"157","author":"Wilson","year":"2016","journal-title":"Endocrinology"},{"key":"2024100410253847900_B66","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/cvr\/cvq360","article-title":"A CD36-dependent pathway enhances macrophage and adipose tissue inflammation and impairs insulin signalling","volume":"89","author":"Kennedy","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"2024100410253847900_B67","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1002\/oby.22985","article-title":"White Adipose Tissue Surface Expression of LDLR and CD36 is Associated with Risk Factors for Type 2 Diabetes in Adults with Obesity","volume":"28","author":"Cyr","year":"2020","journal-title":"Obesity (Silver Spring)."},{"key":"2024100410253847900_B68","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s44321-023-00021-x","article-title":"FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis","volume":"16","author":"Ursic-Bedoya","year":"2024","journal-title":"EMBO Mol. Med."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/138\/20\/1265\/961712\/cs-2024-1137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/138\/20\/1265\/961712\/cs-2024-1137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T10:26:23Z","timestamp":1728037583000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/138\/20\/1265\/234989\/Non-mitogenic-FGF19-mRNA-based-therapy-for-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":68,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024,10,16]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20241137","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,10]]}}}